This company has been acquired
VILG.F Stock Overview
Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, rest of Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Yourgene Health Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.003 |
| 52 Week High | UK£0.07 |
| 52 Week Low | UK£0.0005 |
| Beta | 0.86 |
| 1 Month Change | 0% |
| 3 Month Change | 500.00% |
| 1 Year Change | n/a |
| 3 Year Change | -98.57% |
| 5 Year Change | n/a |
| Change since IPO | -97.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| VILG.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -4.4% | -3.7% |
| 1Y | n/a | -2.8% | 20.2% |
Return vs Industry: Insufficient data to determine how VILG.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how VILG.F performed against the US Market.
Price Volatility
| VILG.F volatility | |
|---|---|
| VILG.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VILG.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine VILG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 253 | Lyn Rees | www.yourgene-health.com |
Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, rest of Europe, and internationally. It develops in vitro diagnostic products, such as IONA Test, a non-invasive pre-natal test (NIPT) for Down’s syndrome, Edwards' syndrome, and Patau’s Syndrome in pregnant women; Cystic Fibrosis Screening tests; Rapid Aneuploidy Analysis, a confirmatory diagnostic test carried out after amniocentesi; and Recurrent Pregnancy Loss, a PCR assay for the routine diagnosis of the six most common chromosomes related to pregnancy loss, as well as DPYD genotyping products. The company also offers Ranger, a technology platform for sample size selection and enrichment; Elucigene DPYD assay, a PCR test to predict a patient’s response to a chemotherapy treatment; and Clarigene SARS-CoV-2 CE-IVD, a PCR assay used for routine COVID-19 testing.
Yourgene Health Plc Fundamentals Summary
| VILG.F fundamental statistics | |
|---|---|
| Market cap | US$20.69m |
| Earnings (TTM) | -US$10.28m |
| Revenue (TTM) | US$37.33m |
0.6x
P/S Ratio-2.0x
P/E RatioIs VILG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VILG.F income statement (TTM) | |
|---|---|
| Revenue | UK£29.67m |
| Cost of Revenue | UK£13.21m |
| Gross Profit | UK£16.46m |
| Other Expenses | UK£24.63m |
| Earnings | -UK£8.17m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0026 |
| Gross Margin | 55.48% |
| Net Profit Margin | -27.55% |
| Debt/Equity Ratio | 15.7% |
How did VILG.F perform over the long term?
See historical performance and comparison